Literature DB >> 17430377

5% 5-Fluorouracil cream for the treatment of small superficial Basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction.

Kenneth Gross1, Leon Kircik, Greg Kricorian.   

Abstract

BACKGROUND: Five percent 5-fluorouracil (5-FU) cream is approved by the FDA for the treatment of superficial basal cell carcinomas but has been underutilized.
OBJECTIVE: The objective was to evaluate the efficacy, tolerability, cosmetic outcome, and patient satisfaction of 5% 5-FU in the treatment of superficial basal cell carcinomas.
MATERIALS AND METHODS: A total of 29 patients with 31 biopsy-proven superficial basal cell carcinoma lesions on the trunk or limbs were treated with 5% 5-FU cream twice daily for up to 12 weeks. Treatment could be stopped sooner if the lesion was clinically resolved. The lesional site was surgically excised 3 weeks after the end of treatment for histologic evaluation of cure. RESULTS The histologic cure rate was 90% (28/31 lesions cured) and the mean time to clinical cure was 10.5 weeks. 5-FU was generally well tolerated with a good cosmetic outcome-the majority of patients had no pain or scarring and only mild erythema. Patients were generally very satisfied with their treatment.
CONCLUSION: Five percent 5-FU is a highly effective and well-tolerated treatment option for superficial basal cell carcinomas offering a generally good cosmetic outcome and high levels of patient satisfaction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17430377     DOI: 10.1111/j.1524-4725.2007.33090.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  18 in total

Review 1.  Surgical Management of Periocular Cancers: High- and Low-Risk Features Drive Treatment.

Authors:  Richard C Allen
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

2.  Nonmelanoma Skin Cancer in Childhood and Young Adult Cancer Survivors Previously Treated With Radiotherapy.

Authors:  Stefanie L Thorsness; Azael Freites-Martinez; Michael A Marchetti; Cristian Navarrete-Dechent; Mario E Lacouture; Emily S Tonorezos
Journal:  J Natl Compr Canc Netw       Date:  2019-03-01       Impact factor: 11.908

Review 3.  Basal Cell Carcinoma: A Comprehensive Review of Existing and Emerging Nonsurgical Therapies.

Authors:  Julien Lanoue; Gary Goldenberg
Journal:  J Clin Aesthet Dermatol       Date:  2016-05-01

Review 4.  An evidence-based surgical algorithm for management of odontogenic keratocyst.

Authors:  Fadekemi Olufunmilayo Oginni; Nasser Alasseri; Oladunni Mojirayo Ogundana; Bamidele Adetokunbo Famurewa; Anthony Pogrel; Essam Ahmed Al-Moraissi
Journal:  Oral Maxillofac Surg       Date:  2022-04-27

5.  A Conservative Combined Laser Cryoimmunotherapy Treatment vs. Surgical Excision for Basal Cell Carcinoma.

Authors:  Lucian G Scurtu; Marian Petrica; Mariana Grigore; Alina Avram; Ionel Popescu; Olga Simionescu
Journal:  J Clin Med       Date:  2022-06-15       Impact factor: 4.964

6.  STAR particles for enhanced topical drug and vaccine delivery.

Authors:  Andrew R Tadros; Andrey Romanyuk; Ian C Miller; Andrea Santiago; Richard K Noel; Laura O'Farrell; Gabriel A Kwong; Mark R Prausnitz
Journal:  Nat Med       Date:  2020-03-09       Impact factor: 53.440

7.  Skin cancer and the solid organ transplant recipient.

Authors:  M J Patel; N J Liégeois
Journal:  Curr Treat Options Oncol       Date:  2009-02-19

8.  Nonsurgical Options for the Treatment of Basal Cell Carcinoma.

Authors:  John Paoli; Johan Dahlén Gyllencreutz; Julia Fougelberg; Eva Johansson Backman; Maja Modin; Sam Polesie; Oscar Zaar
Journal:  Dermatol Pract Concept       Date:  2019-04-30

9.  Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease.

Authors:  Daniela Göppner; Martin Leverkus
Journal:  J Skin Cancer       Date:  2010-12-29

Review 10.  Skin Penetration Enhancement Strategies Used in the Development of Melanoma Topical Treatments.

Authors:  Supreeda Tambunlertchai; Sean M Geary; Aliasger K Salem
Journal:  AAPS J       Date:  2021-01-06       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.